High IgE levels to α‐lactalbumin, β‐lactoglobulin and casein predict less successful cow's milk oral immunotherapy

Background A new treatment option for persistent cow's milk allergy (CMA) is oral immunotherapy (OIT). Not all patients develop tolerance during therapy, and markers to identify those who will benefit from it are needed. The objective was to study the IgE and IgG4 antibody profiles to milk and...

Full description

Saved in:
Bibliographic Details
Published inAllergy (Copenhagen) Vol. 70; no. 8; pp. 955 - 962
Main Authors Kuitunen, M., Englund, H., Remes, S., Movérare, R., Pelkonen, A., Borres, M. P., Mäkelä, M. J.
Format Journal Article
LanguageEnglish
Published Denmark 01.08.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background A new treatment option for persistent cow's milk allergy (CMA) is oral immunotherapy (OIT). Not all patients develop tolerance during therapy, and markers to identify those who will benefit from it are needed. The objective was to study the IgE and IgG4 antibody profiles to milk and milk proteins before and after OIT in relation to clinical outcome. Methods Seventy‐six children (5–17 years) with challenge‐verified CMA were subjected to a 6‐month OIT protocol. The treatment aimed at reaching a maintenance dose of 200 ml CM (high dose = HD). Those who did not reach target were analysed as a low‐dose (LD) group. Sera were characterized before and after OIT regarding serum levels of IgE and IgG4 to milk and five milk allergen components evaluated together with clinical CMA symptoms and outcome of OIT. Results Fifty‐five (72%) patients reached the maintenance dose (HD) during therapy. High specific IgE levels towards the milk allergens α‐lactalbumin (P = 0.048), β‐lactoglobulin (P = 0.006) and casein (P = 0.015) before OIT start were associated with lower maintenance dose reached. Patients who developed desensitization had a larger increase in IgG4 levels to α‐lactalbumin (P = 0.034), β‐lactoglobulin (P = 0.010), casein (P = 0.047) and lactoferrin (P = 0.030) during treatment than those who failed. Conclusions Component‐resolved diagnostics before OIT can help to identify children with lower probability of a successful OIT outcome, as high IgE levels to α‐lactalbumin, β‐lactoglobulin and casein are associated with lower maintenance dose reached. An increase in the IgG4 concentration to milk components during treatment indicated effective desensitization.
AbstractList A new treatment option for persistent cow's milk allergy (CMA) is oral immunotherapy (OIT). Not all patients develop tolerance during therapy, and markers to identify those who will benefit from it are needed. The objective was to study the IgE and IgG4 antibody profiles to milk and milk proteins before and after OIT in relation to clinical outcome. Seventy-six children (5-17 years) with challenge-verified CMA were subjected to a 6-month OIT protocol. The treatment aimed at reaching a maintenance dose of 200 ml CM (high dose = HD). Those who did not reach target were analysed as a low-dose (LD) group. Sera were characterized before and after OIT regarding serum levels of IgE and IgG4 to milk and five milk allergen components evaluated together with clinical CMA symptoms and outcome of OIT. Fifty-five (72%) patients reached the maintenance dose (HD) during therapy. High specific IgE levels towards the milk allergens α-lactalbumin (P = 0.048), β-lactoglobulin (P = 0.006) and casein (P = 0.015) before OIT start were associated with lower maintenance dose reached. Patients who developed desensitization had a larger increase in IgG4 levels to α-lactalbumin (P = 0.034), β-lactoglobulin (P = 0.010), casein (P = 0.047) and lactoferrin (P = 0.030) during treatment than those who failed. Component-resolved diagnostics before OIT can help to identify children with lower probability of a successful OIT outcome, as high IgE levels to α-lactalbumin, β-lactoglobulin and casein are associated with lower maintenance dose reached. An increase in the IgG4 concentration to milk components during treatment indicated effective desensitization.
Abstract Background A new treatment option for persistent cow's milk allergy ( CMA ) is oral immunotherapy ( OIT ). Not all patients develop tolerance during therapy, and markers to identify those who will benefit from it are needed. The objective was to study the IgE and IgG 4 antibody profiles to milk and milk proteins before and after OIT in relation to clinical outcome. Methods Seventy‐six children (5–17 years) with challenge‐verified CMA were subjected to a 6‐month OIT protocol. The treatment aimed at reaching a maintenance dose of 200 ml CM (high dose =  HD ). Those who did not reach target were analysed as a low‐dose ( LD ) group. Sera were characterized before and after OIT regarding serum levels of IgE and IgG 4 to milk and five milk allergen components evaluated together with clinical CMA symptoms and outcome of OIT . Results Fifty‐five (72%) patients reached the maintenance dose ( HD ) during therapy. High specific IgE levels towards the milk allergens α‐lactalbumin ( P  =   0.048), β‐lactoglobulin ( P  =   0.006) and casein ( P  =   0.015) before OIT start were associated with lower maintenance dose reached. Patients who developed desensitization had a larger increase in IgG 4 levels to α‐lactalbumin ( P  =   0.034), β‐lactoglobulin ( P  =   0.010), casein ( P  =   0.047) and lactoferrin ( P  =   0.030) during treatment than those who failed. Conclusions Component‐resolved diagnostics before OIT can help to identify children with lower probability of a successful OIT outcome, as high IgE levels to α‐lactalbumin, β‐lactoglobulin and casein are associated with lower maintenance dose reached. An increase in the IgG 4 concentration to milk components during treatment indicated effective desensitization.
Background A new treatment option for persistent cow's milk allergy (CMA) is oral immunotherapy (OIT). Not all patients develop tolerance during therapy, and markers to identify those who will benefit from it are needed. The objective was to study the IgE and IgG4 antibody profiles to milk and milk proteins before and after OIT in relation to clinical outcome. Methods Seventy‐six children (5–17 years) with challenge‐verified CMA were subjected to a 6‐month OIT protocol. The treatment aimed at reaching a maintenance dose of 200 ml CM (high dose = HD). Those who did not reach target were analysed as a low‐dose (LD) group. Sera were characterized before and after OIT regarding serum levels of IgE and IgG4 to milk and five milk allergen components evaluated together with clinical CMA symptoms and outcome of OIT. Results Fifty‐five (72%) patients reached the maintenance dose (HD) during therapy. High specific IgE levels towards the milk allergens α‐lactalbumin (P = 0.048), β‐lactoglobulin (P = 0.006) and casein (P = 0.015) before OIT start were associated with lower maintenance dose reached. Patients who developed desensitization had a larger increase in IgG4 levels to α‐lactalbumin (P = 0.034), β‐lactoglobulin (P = 0.010), casein (P = 0.047) and lactoferrin (P = 0.030) during treatment than those who failed. Conclusions Component‐resolved diagnostics before OIT can help to identify children with lower probability of a successful OIT outcome, as high IgE levels to α‐lactalbumin, β‐lactoglobulin and casein are associated with lower maintenance dose reached. An increase in the IgG4 concentration to milk components during treatment indicated effective desensitization.
Author Kuitunen, M.
Englund, H.
Remes, S.
Movérare, R.
Pelkonen, A.
Mäkelä, M. J.
Borres, M. P.
Author_xml – sequence: 1
  givenname: M.
  surname: Kuitunen
  fullname: Kuitunen, M.
  organization: University of Helsinki
– sequence: 2
  givenname: H.
  surname: Englund
  fullname: Englund, H.
  organization: Thermo Fisher Scientific
– sequence: 3
  givenname: S.
  surname: Remes
  fullname: Remes, S.
  organization: University of Eastern
– sequence: 4
  givenname: R.
  surname: Movérare
  fullname: Movérare, R.
  organization: Uppsala University
– sequence: 5
  givenname: A.
  surname: Pelkonen
  fullname: Pelkonen, A.
  organization: University of Helsinki
– sequence: 6
  givenname: M. P.
  surname: Borres
  fullname: Borres, M. P.
  organization: Uppsala University
– sequence: 7
  givenname: M. J.
  surname: Mäkelä
  fullname: Mäkelä, M. J.
  organization: University of Helsinki
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25951431$$D View this record in MEDLINE/PubMed
BookMark eNp1kEtOwzAQhi1URB-w4ALIO4REWj-SOl5WVaGVIrGBdeTYTmtwHooTSnccgavAQXoITkJKgB0jjWY0-vRr9A1BLy9yDcA5RmPc1kRYO8Zk6rMjMMCUhx7nPOiBAcIo8PyAhn0wdO4RIcQIRyegTwIeYJ_iAXhZmvUGrtYLaPWztg7WBdy_f76-WSFrYZMmM_k13H_8XIq1LZLGmhyKXEEpnG7XstLKyLpNcA66Rsp2po2FstheOpgZ-wSLSlhosqzJi3qjK1HuTsFxKqzTZz9zBB5uFvfzpRfd3a7ms8iThDHm4ZQwLoU6tE7anxFKAsJFSnRAsQpVypQfasQkTZTivtYhC4SkUylISimnI3DV5cqqcK7SaVxWJhPVLsYoPtiLW3vxt72WvejYskkyrf7IX10tMOmArbF6939SPIuiLvILXnKA_g
CitedBy_id crossref_primary_10_1016_j_waojou_2019_100091
crossref_primary_10_1097_ACI_0000000000000491
crossref_primary_10_1016_j_reval_2017_07_013
crossref_primary_10_1111_pai_12653
crossref_primary_10_1016_j_alit_2016_07_002
crossref_primary_10_1186_s13601_016_0131_x
crossref_primary_10_1111_pai_13442
crossref_primary_10_1016_j_alit_2020_03_008
crossref_primary_10_1021_acs_jafc_5b01782
crossref_primary_10_1111_pai_13025
crossref_primary_10_26416_Aler_8_1_2024_9438
crossref_primary_10_1002_iid3_218
crossref_primary_10_1111_all_13179
crossref_primary_10_1111_pai_12958
crossref_primary_10_1111_all_12780
crossref_primary_10_1111_all_13132
crossref_primary_10_1016_j_anai_2017_11_016
crossref_primary_10_1111_all_15479
crossref_primary_10_1007_s40521_019_00205_2
crossref_primary_10_1002_2211_5463_12656
crossref_primary_10_1007_s11882_016_0610_0
crossref_primary_10_1016_j_jaci_2016_09_007
crossref_primary_10_2500_aap_2021_42_200129
crossref_primary_10_1016_j_jaip_2019_01_022
crossref_primary_10_1038_s41598_017_16730_6
crossref_primary_10_1111_apa_13550
crossref_primary_10_1002_iid3_294
crossref_primary_10_1111_apa_14226
crossref_primary_10_1186_s12887_020_1971_z
crossref_primary_10_1016_j_rgmx_2022_03_007
crossref_primary_10_1016_j_vaccine_2017_02_009
crossref_primary_10_3390_nu14030629
crossref_primary_10_1016_j_rgmxen_2022_01_002
crossref_primary_10_3389_fimmu_2021_704633
crossref_primary_10_1111_all_15266
crossref_primary_10_3390_nu14040822
crossref_primary_10_1016_j_jaci_2021_02_012
crossref_primary_10_1111_cea_13469
crossref_primary_10_1097_ACI_0000000000000756
crossref_primary_10_3390_nu14030494
crossref_primary_10_1089_ped_2016_0679
crossref_primary_10_1016_j_reval_2016_10_010
crossref_primary_10_1016_j_jaip_2021_11_005
crossref_primary_10_1007_s00105_017_3958_8
Cites_doi 10.1111/j.1398-9995.2010.02429.x
10.1016/j.jaci.2005.06.018
10.1111/pai.12077
10.1016/j.jaci.2008.09.030
10.1111/j.1365-2222.2009.03409.x
10.1111/j.1365-2222.2007.02749.x
10.1016/j.jaci.2006.09.016
10.1111/cea.12273
10.1111/j.1398-9995.2008.01705.x
10.1016/j.jaci.2012.06.049
10.1111/j.1398-9995.2004.00542.x
10.1016/S0140-6736(13)60309-8
10.1111/pai.12100
10.1016/j.jaci.2013.12.1088
10.1016/j.jaci.2011.10.023
10.1016/j.jaci.2008.06.002
10.1111/j.1399-3038.2007.00670.x
10.1186/1939-4551-6-17
10.1111/j.1365-2222.2011.03749.x
10.1111/j.1651-2227.2012.02815.x
10.1016/S0140-6736(13)62301-6
10.1016/j.anai.2013.01.013
10.1016/j.jaci.2007.10.029
10.1111/j.1398-9995.2007.01501.x
10.1016/j.jaci.2010.04.030
10.1111/pai.12186
10.1056/NEJMoa1200435
10.1186/1476-7961-10-1
10.1111/j.1365-2222.2011.03948.x
10.1016/j.jaci.2009.05.022
10.1016/j.jaci.2008.05.043
ContentType Journal Article
Copyright 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Copyright_xml – notice: 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
– notice: 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
DOI 10.1111/all.12647
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList MEDLINE
CrossRef

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1398-9995
EndPage 962
ExternalDocumentID 10_1111_all_12647
25951431
ALL12647
Genre article
Research Support, Non-U.S. Gov't
Journal Article
Comparative Study
GrantInformation_xml – fundername: Foundation for Pediatric Research
– fundername: Helsinki University Central Hospital Research Fund
GroupedDBID .3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
23M
24P
2WC
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8F7
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAKAS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHEFC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
AOETA
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
E3Z
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
P6G
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
TR2
UB1
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
Y6R
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
ID FETCH-LOGICAL-c2777-1f279cad9cadeb14300b529af2e531d8df7d48e07c3bdd94ee875ac36ca2f3393
IEDL.DBID DR2
ISSN 0105-4538
IngestDate Fri Aug 23 01:12:35 EDT 2024
Sat Sep 28 08:12:47 EDT 2024
Sat Aug 24 00:54:22 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords cow's milk allergy
oral immunotherapy
specific IgE
specific IgG4
desensitization
Language English
License 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2777-1f279cad9cadeb14300b529af2e531d8df7d48e07c3bdd94ee875ac36ca2f3393
PMID 25951431
PageCount 8
ParticipantIDs crossref_primary_10_1111_all_12647
pubmed_primary_25951431
wiley_primary_10_1111_all_12647_ALL12647
PublicationCentury 2000
PublicationDate August 2015
PublicationDateYYYYMMDD 2015-08-01
PublicationDate_xml – month: 08
  year: 2015
  text: August 2015
PublicationDecade 2010
PublicationPlace Denmark
PublicationPlace_xml – name: Denmark
PublicationTitle Allergy (Copenhagen)
PublicationTitleAlternate Allergy
PublicationYear 2015
References 2013; 24
2008; 19
2010; 126
2005; 116
2014; 25
2013; 102
2013; 382
2012; 367
2008; 122
2014; 133
2008; 121
2013; 6
2012; 10
2012; 129
2010; 40
2014; 44
2007; 37
2010; 65
2007; 119
2004; 59
2011; 41
2009; 124
2007; 62
2013; 110
2008; 63
2013; 131
2014; 383
2012; 42
e_1_2_11_10_1
e_1_2_11_32_1
e_1_2_11_31_1
e_1_2_11_30_1
e_1_2_11_14_1
e_1_2_11_13_1
e_1_2_11_12_1
e_1_2_11_11_1
e_1_2_11_7_1
e_1_2_11_29_1
e_1_2_11_6_1
e_1_2_11_28_1
e_1_2_11_5_1
e_1_2_11_27_1
e_1_2_11_4_1
e_1_2_11_26_1
e_1_2_11_3_1
e_1_2_11_2_1
e_1_2_11_21_1
e_1_2_11_20_1
e_1_2_11_25_1
e_1_2_11_24_1
e_1_2_11_9_1
e_1_2_11_23_1
e_1_2_11_8_1
e_1_2_11_22_1
e_1_2_11_18_1
e_1_2_11_17_1
e_1_2_11_16_1
e_1_2_11_15_1
e_1_2_11_19_1
References_xml – volume: 124
  start-page: 292
  year: 2009
  end-page: 300
  article-title: Clinical efficacy and immune regulation with peanut oral immunotherapy
  publication-title: J Allergy Clin Immunol
– volume: 129
  start-page: 448
  year: 2012
  end-page: 455
  article-title: The safety and efficacy of sublingual and oral immunotherapy for milk allergy
  publication-title: J Allergy Clin Immunol
– volume: 102
  start-page: 172
  year: 2013
  end-page: 176
  article-title: Milk oral immunotherapy is effective in school‐aged children
  publication-title: Acta Paediatr
– volume: 25
  start-page: 227
  year: 2014
  end-page: 235
  article-title: Use of IgE and IgG4 epitope binding to predict the outcome of oral immunotherapy in cow's milk allergy
  publication-title: Pediatr Allergy Immunol
– volume: 6
  start-page: 17
  year: 2013
  article-title: A WAO ‐ ARIA ‐ GA(2)LEN consensus document on molecular‐based allergy diagnostics
  publication-title: World Allergy Organ J
– volume: 24
  start-page: 512
  year: 2013
  end-page: 520
  article-title: Oral immunotherapy and tolerance induction in childhood
  publication-title: Pediatr Allergy Immunol
– volume: 65
  start-page: 1554
  year: 2010
  end-page: 1557
  article-title: The role of hen's egg‐specific IgE, IgG and IgG4 in the diagnostic procedure of hen's egg allergy
  publication-title: Allergy
– volume: 110
  start-page: 290
  year: 2013
  end-page: 294
  article-title: Efficacy and safety of oral desensitization in children with cow's milk allergy according to their serum specific IgE level
  publication-title: Ann Allergy Asthma Immunol
– volume: 383
  start-page: 1297
  year: 2014
  end-page: 1304
  article-title: Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial
  publication-title: Lancet
– volume: 44
  start-page: 579
  year: 2014
  end-page: 588
  article-title: Ovalbumin‐specific IgE/IgG4 ratio might improve the prediction of cooked and uncooked egg tolerance development in egg‐allergic children
  publication-title: Clin Exp Allergy
– volume: 367
  start-page: 233
  year: 2012
  end-page: 243
  article-title: Oral immunotherapy for treatment of egg allergy in children
  publication-title: N Engl J Med
– volume: 59
  start-page: 980
  year: 2004
  end-page: 987
  article-title: A protocol for oral desensitization in children with IgE‐mediated cow's milk allergy
  publication-title: Allergy
– volume: 37
  start-page: 1103
  year: 2007
  end-page: 1110
  article-title: Maintenance of tolerance to cow's milk in atopic individuals is characterized by high levels of specific immunoglobulin G4
  publication-title: Clin Exp Allergy
– volume: 24
  start-page: 376
  year: 2013
  end-page: 381
  article-title: Comparison between two maintenance feeding regimens after successful cow's milk oral desensitization
  publication-title: Pediatr Allergy Immunol
– volume: 122
  start-page: 418
  year: 2008
  end-page: 419
  article-title: Rush oral immunotherapy in children with persistent cow's milk allergy
  publication-title: J Allergy Clin Immunol
– volume: 131
  start-page: 222
  year: 2013
  end-page: 224
  article-title: Utility of casein‐specific IgE levels in predicting reactivity to baked milk
  publication-title: J Allergy Clin Immunol
– volume: 42
  start-page: 363
  year: 2012
  end-page: 374
  article-title: Oral immunotherapy for IgE‐mediated cow's milk allergy: a systematic review and meta‐analysis
  publication-title: Clin Exp Allergy
– volume: 40
  start-page: 251
  year: 2010
  end-page: 256
  article-title: Duration of clinical reactivity in cow's milk allergy is associated with levels of specific immunoglobulin G4 and immunoglobulin A antibodies to beta‐lactoglobulin
  publication-title: Clin Exp Allergy
– volume: 19
  start-page: 412
  year: 2008
  end-page: 419
  article-title: Oral desensitization in children with immunoglobulin E‐mediated cow's milk allergy–follow‐up at 4 yr and 8 months
  publication-title: Pediatr Allergy Immunol
– volume: 62
  start-page: 1261
  year: 2007
  end-page: 1269
  article-title: Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction
  publication-title: Allergy
– volume: 63
  start-page: 793
  year: 2008
  end-page: 796
  article-title: Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report
  publication-title: Allergy
– volume: 119
  start-page: 199
  year: 2007
  end-page: 205
  article-title: Egg oral immunotherapy in nonanaphylactic children with egg allergy
  publication-title: J Allergy Clin Immunol
– volume: 122
  start-page: 342
  year: 2008
  end-page: 347
  article-title: Tolerance to extensively heated milk in children with cow's milk allergy
  publication-title: J Allergy Clin Immunol
– volume: 122
  start-page: 1154
  year: 2008
  end-page: 1160
  article-title: A randomized, double‐blind, placebo‐controlled study of milk oral immunotherapy for cow's milk allergy
  publication-title: J Allergy Clin Immunol
– volume: 121
  start-page: 343
  year: 2008
  end-page: 347
  article-title: Specific oral tolerance induction in children with very severe cow's milk‐induced reactions
  publication-title: J Allergy Clin Immunol
– volume: 116
  start-page: 869
  year: 2005
  end-page: 875
  article-title: Clinical course and prognosis of cow's milk allergy are dependent on milk‐specific IgE status
  publication-title: J Allergy Clin Immunol
– volume: 133
  start-page: 621
  year: 2014
  end-page: 631
  article-title: Mechanisms of allergen‐specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens
  publication-title: J Allergy Clin Immunol
– volume: 41
  start-page: 1297
  year: 2011
  end-page: 1304
  article-title: Oral desensitization as a useful treatment in 2‐year‐old children with cow's milk allergy
  publication-title: Clin Exp Allergy
– volume: 10
  start-page: 1
  year: 2012
  article-title: The usefulness of casein‐specific IgE and IgG4 antibodies in cow's milk allergic children
  publication-title: Clin Mol Allergy
– volume: 382
  start-page: 1656
  year: 2013
  end-page: 1664
  article-title: IgE‐mediated food allergy in children
  publication-title: Lancet
– volume: 126
  start-page: 83
  year: 2010
  end-page: 91
  article-title: Oral peanut immunotherapy in children with peanut anaphylaxis
  publication-title: J Allergy Clin Immunol
– ident: e_1_2_11_27_1
  doi: 10.1111/j.1398-9995.2010.02429.x
– ident: e_1_2_11_2_1
  doi: 10.1016/j.jaci.2005.06.018
– ident: e_1_2_11_23_1
  doi: 10.1111/pai.12077
– ident: e_1_2_11_13_1
  doi: 10.1016/j.jaci.2008.09.030
– ident: e_1_2_11_25_1
  doi: 10.1111/j.1365-2222.2009.03409.x
– ident: e_1_2_11_31_1
  doi: 10.1111/j.1365-2222.2007.02749.x
– ident: e_1_2_11_15_1
  doi: 10.1016/j.jaci.2006.09.016
– ident: e_1_2_11_28_1
  doi: 10.1111/cea.12273
– ident: e_1_2_11_30_1
  doi: 10.1111/j.1398-9995.2008.01705.x
– ident: e_1_2_11_21_1
  doi: 10.1016/j.jaci.2012.06.049
– ident: e_1_2_11_6_1
  doi: 10.1111/j.1398-9995.2004.00542.x
– ident: e_1_2_11_5_1
  doi: 10.1016/S0140-6736(13)60309-8
– ident: e_1_2_11_7_1
  doi: 10.1111/pai.12100
– ident: e_1_2_11_29_1
  doi: 10.1016/j.jaci.2013.12.1088
– ident: e_1_2_11_32_1
  doi: 10.1016/j.jaci.2011.10.023
– ident: e_1_2_11_8_1
  doi: 10.1016/j.jaci.2008.06.002
– ident: e_1_2_11_12_1
  doi: 10.1111/j.1399-3038.2007.00670.x
– ident: e_1_2_11_17_1
  doi: 10.1186/1939-4551-6-17
– ident: e_1_2_11_10_1
  doi: 10.1111/j.1365-2222.2011.03749.x
– ident: e_1_2_11_19_1
  doi: 10.1111/j.1651-2227.2012.02815.x
– ident: e_1_2_11_20_1
  doi: 10.1016/S0140-6736(13)62301-6
– ident: e_1_2_11_18_1
  doi: 10.1016/j.anai.2013.01.013
– ident: e_1_2_11_4_1
  doi: 10.1016/j.jaci.2007.10.029
– ident: e_1_2_11_11_1
  doi: 10.1111/j.1398-9995.2007.01501.x
– ident: e_1_2_11_14_1
  doi: 10.1016/j.jaci.2010.04.030
– ident: e_1_2_11_22_1
  doi: 10.1111/pai.12186
– ident: e_1_2_11_16_1
  doi: 10.1056/NEJMoa1200435
– ident: e_1_2_11_26_1
  doi: 10.1186/1476-7961-10-1
– ident: e_1_2_11_3_1
  doi: 10.1111/j.1365-2222.2011.03948.x
– ident: e_1_2_11_9_1
  doi: 10.1016/j.jaci.2009.05.022
– ident: e_1_2_11_24_1
  doi: 10.1016/j.jaci.2008.05.043
SSID ssj0007290
Score 2.397608
Snippet Background A new treatment option for persistent cow's milk allergy (CMA) is oral immunotherapy (OIT). Not all patients develop tolerance during therapy, and...
A new treatment option for persistent cow's milk allergy (CMA) is oral immunotherapy (OIT). Not all patients develop tolerance during therapy, and markers to...
Abstract Background A new treatment option for persistent cow's milk allergy ( CMA ) is oral immunotherapy ( OIT ). Not all patients develop tolerance during...
SourceID crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 955
SubjectTerms Administration, Oral
Adolescent
Animals
Biomarkers - blood
Caseins - blood
Caseins - immunology
Cattle
Child
Child, Preschool
Cohort Studies
cow's milk allergy
desensitization
Desensitization, Immunologic - methods
Female
Follow-Up Studies
Humans
Immunoglobulin E - blood
Immunotherapy - methods
Lactalbumin - blood
Lactalbumin - immunology
Male
Milk - adverse effects
Milk - immunology
Milk Hypersensitivity - blood
Milk Hypersensitivity - diagnosis
Milk Hypersensitivity - therapy
oral immunotherapy
Predictive Value of Tests
Prospective Studies
Risk Assessment
specific IgE
specific IgG4
Statistics, Nonparametric
Treatment Outcome
Title High IgE levels to α‐lactalbumin, β‐lactoglobulin and casein predict less successful cow's milk oral immunotherapy
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fall.12647
https://www.ncbi.nlm.nih.gov/pubmed/25951431
Volume 70
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFA7ig_ji_TJvBBH0wY4uaZcGn4ZuTFEfxMEehJFLI8Paydrh5cmf4F_RH7If4S8xp-3mBQTxoRBKctomOTkn6Xe-g9AOMSygrgkcRlzheMCsza1ZdDxfaOEbzmUAgcJn59Vmyztp--0JdDCKhcn5IcYHbqAZ2XoNCi5k8kXJRRSVK9acQyR5hTKAcx1dfFJHseJ8xfoP9sE0KFiFAMUzbvnNFo0N0FcnNbMyjVl0NXq_HFxyUx6ksqyeflA3_vMD5tBM4X3iWj5d5tFEGC-gqbPi__oiegDYBz6-ruMIwEQJTnt4-Pr-_BIJlWZI5m68j4dvxZ0e0IkAlB2LWGNlDaIt3vVBXGolJAlOBllCRjOIsOrd7yb4thvdYGAFwF2ITCnivx6XUKtRvzxsOkVuBkcRxphTMYRxJTRcdrn3qOtKn3BhSGi1WgfaMO0FocsUlVpzLwztxkgoWlWCGEo5XUaTcS8OVxEOVJUYwoFpzED660BzJqXPq8qKkUqX0PZolDp3OQVHZ7R1sX3YyfqwhFby8RtXsfs6cAYrJbSXjcLvbTu109OssPb3quto2rpOfg4F3ECTaX8Qblr3JJVb2Tz8AE5i5LA
link.rule.ids 315,783,787,1378,27936,27937,46306,46730
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NatwwEB7SFNpekjZtms1PK0KhPdSLV7JXFvQS8sMm2c2hJJBLMbJklSWuN8Re8nPKI-RV0gfJQ-RJMmN7t2mhUHowCCPJsqTRjKRvvgH4wJ2MhO8iT3JfewExaytUi14QaqtDp1QSkaPw4KDbOwr2jsPjGfgy8YWp-SGmB24kGdV6TQJOB9KPpFxnWbuD-lw-gaco7oICN2x9_UUeJZsTFrQg8NMianiFCMczLfqbNpqqoMdmaqVndubh26SFNbzkpD0uk7a5-oO88X9_4SXMNQYo26hnzCuYSfMFeDZorthfwwUhP9ju922WEZ6oYOWI3d3eX99k2pQVmHmYf2Z3P5s3I2IUITQ707llBnUiJk_PqLoSaygKVoyrmIzYJmZG5x8L9mOYnTAiBmBDck5pXMAu38DRzvbhZs9rwjN4hkspvY7jUhlt6cEVPxC-n4RcacdTFGwbWSdtEKW-NCKxVgVpinsjbUTXaO6EUGIRZvNRni4Bi0yXO66IbMxRBOzIKpkkoeoarCYxtgXrk2GKT2sWjniye8E-jKs-bMHbegCnWXBrR_ZgpwWfqmH4e9l4o9-vEsv_nvU9PO8dDvpxf_dgfwVeoCUV1sjAVZgtz8bpGlorZfKumpQPg8LoyA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bSuQwGP7xAOLNup7HYxBBL-zQSQ9p8ErUwcMoy6LghVDSpJFhuu0w7bDrXu0j7KvsPogPsU-y-dvO6AoL4kUhlCRtk_z5v6Tf_wVgl2oWOLYOLEZtYbmorM2NW7RcTyjhac6jAAOFr679s1v34s67m4DDUSxMpQ8x3nBDyyjnazTwvtIvjFwkSbNl3DmbhGnXN8gXEdHnZ-0oVm-wGABhnuwEtawQ0njGRf9xRmMP9BKllm6mPQf3oxes2CW95rCImvL7K-3Gd37BR_hQw09yVI2XeZiI0wWYuap_sC_CN-R9kPOHU5IgmygnRUaefv358TMRsiipzN30gDz9ru9kqCeCXHYiUkWk8Ygm2R9gdYWpIc9JPixPZNTDhMjs615OvnSTHkFZANLF0JQ6AOxxCW7bpzfHZ1Z9OIMlKWPMamnKuBQKLzPfu45tRx7lQtPYmLUKlGbKDWKbSSdSirtxbFZGQjq-FFQ7DneWYSrN0ngVSCB9qilHqTGN518HirMo8rgvTTWRVA3YGfVS2K80OMLR2sW0YVi2YQNWqv4bZzELO0SDrQbsl73w_7LhUadTJtbennUbZj6dtMPO-fXlOswaGOVVtMANmCoGw3jTQJUi2iqH5F_urud3
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High+IgE+levels+to+%CE%B1%E2%80%90lactalbumin%2C+%CE%B2%E2%80%90lactoglobulin+and+casein+predict+less+successful+cow%27s+milk+oral+immunotherapy&rft.jtitle=Allergy+%28Copenhagen%29&rft.au=Kuitunen%2C+M.&rft.au=Englund%2C+H.&rft.au=Remes%2C+S.&rft.au=Mov%C3%A9rare%2C+R.&rft.date=2015-08-01&rft.issn=0105-4538&rft.eissn=1398-9995&rft.volume=70&rft.issue=8&rft.spage=955&rft.epage=962&rft_id=info:doi/10.1111%2Fall.12647&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_all_12647
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0105-4538&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0105-4538&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0105-4538&client=summon